2 results
Approved WMOCompleted
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
Approved WMOWill not start
1 Confirm comparable results in reduction and consolidation of the fracture fragments using the LFN vs the UFN2 Identifying a significant difference in the soft tissue damage between the LFN and the UFN